Search for dissertations about: "Follicular B cell"
Showing result 11 - 15 of 59 swedish dissertations containing the words Follicular B cell.
-
11. Pattern recognition and iNKT cell regulation of B cell activation
Abstract : The immune system protects individuals against infections but can cause disease if the response is unbalanced. Immune responses include both innate and adaptive response, and these systems are connected. As the first line of defense, innate immune responses are immediately induced upon infection. READ MORE
-
12. Regulation of the germinal center response by T follicular helper cells and type I interferons
Abstract : The protective effect of most currently available vaccines is dependent on high-affinity antibodies and long lived B cell memory, which develop within organized structures of secondary lymphoid organs called germinal centers (GCs). GC formation is supported by T follicular helper (Tfh) cells, a subset of CD4+ T cells that develop in parallel to other effector T cells and specifically localizes to B cell follicles. READ MORE
-
13. Biological pathways in B-cell non-Hodgkin's lymphoma
Abstract : Non-Hodgkin’s lymphomas have become more prevalent in the past 20 years. They constitute a diverse group of lymphoid tumors that have been understood and classified according to their clinical behaviour, anatomic location, morphology, immunophenotype, cytogenetics, and gene expression profile. READ MORE
-
14. Soluble intercellular and vascular cell adhesion molecules-1 in lymphoid neoplasms : A clinical and prognostic study of Hodgkin's disease, non-Hodgkin's lymphomas and chronic B-lymphocytic leukaemia
Abstract : The interaction of soluble adhesion molecules with adhesion ligands expressed by immunological cells interfere with the cell-cell adhesion essential for the signal transductions that initiate immunological responses. Preliminary data suggest that soluble adhesion molecules also promote angiogenesis. READ MORE
-
15. Bruton tyrosine kinase in immunodeficiency and in B-cell malignancy
Abstract : BTK inhibitors have induced high response rates in the treatment of leukemias and lymphomas. Ibrutinib is the first-in-class US Food and Drug Administration (FDA)-approved BTK covalent inhibitor to treat chronic lymphocytic leukemia (CLL). However, a sub-group of patients develops resistance to ibrutinib therapy. READ MORE